Aridis Pharmaceuticals

$6.93
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.18 (-2.59%) Today
+$0.10 (+1.49%) As of 1:00 PM EST after-hours

Why Robinhood?

You can buy or sell ARDS and other stocks, options, and ETFs commission-free!

About ARDS

Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-105, AR-101, AR-401, AR-201, and AR-501. The company was founded by Eric J. Patzer and Vu L. Truong in 2003 and is headquartered in San Jose, CA. The listed name for ARDS is Aridis Pharmaceuticals Inc. Common Stock.

CEO
Vu L. Truong
Employees
25
Headquarters
San Jose, California
Founded
2003
Market Cap
68.73M
Price-Earnings Ratio
Dividend Yield
Average Volume
7.03K
High Today
$7.04
Low Today
$6.82
Open Price
$6.86
Volume
1.25K
52 Week High
$10.18
52 Week Low
$3.80

Collections

ARDS Earnings

-$1.55
-$1.03
-$0.52
$0.00
Q4 FY18
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Estimated
-$0.63 per share
Actual
-$0.65 per share

You May Also Like